Last Updated:
Searching
Create account to add to watchlist!

Golden Arrow Merger Corp. - GAMC

  • Commons

    $9.72

    -0.10%

    GAMC Vol: 377.0

  • Warrants

    $0.54

    -1.82%

    GAMCW Vol: 1.6K

  • Units

    $9.92

    +0.40%

    GAMCU Vol: 1.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 279.7M
Average Volume: 114.1K
52W Range: $9.50 - $16.00
Weekly %: -0.31%
Monthly %: -0.46%
Inst Owners: 43

Info

Target: Searching
Days Since IPO: 256
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-third of one redeemable warrant
Trust Size: 25000000.0M

Management

Our directors, director nominees and executive officers are as follows: Name Age Title Timothy Babich 44 Chief Executive Officer and Chief Financial Officer Jacob Doft 51 Chairman of the Board Lance Hirt 53 Director Andrew Rechtschaffen 43 Director Brett Barth 49 Director Nominee Lloyd Dean 70 Director Nominee Steven Klosk 63 Director Nominee Director Nominee Timothy Babich has served as our Chief Executive Officer and Chief Financial Officer since our inception. In 2018, Mr. Babich founded, and he continues to manage, Nexxus Holdings, an investment firm primarily dedicated to managing his investments. In addition, Mr. Babich was the founder and chairman of FCM Bank, a European based, online challenger bank. FCM Bank was founded in 2012 and sold in 2017 to a private European payments platform. Mr. Babich also is the co-founder of the RUNX1 Research Program, a medical foundation dedicated to finding a cure for an inherited predisposition to leukemia. In 2006, Mr. Babich founded and was CEO of Fortelus Capital Management, a London-based, multi-billion dollar investment manager focused on European special situation investments. Prior to founding Fortelus in 2006, Mr. Babich was a Member of the General Partner at Silver Point Capital, a Greenwich, CT-based special situations fund. He joined Silver Point’s founder in early 2001 after the founder retired as head of Goldman Sachs’ Global Special Situations Group. Mr. Babich graduated from the University of Pennsylvania in 1999, summa cum laude, with undergraduate degrees from Wharton and Engineering (Computer Sciences) as part of the Management & Technology (M&T) dual degree program, along with an MBA from Wharton. He currently serves as Chairman of the Board for the M&T program. Jacob Doft has served as Chairman of our board of directors since our inception. In 1995, Mr. Doft co-founded Highline Capital Management, L.P., a New York-based investment management firm, where he currently serves as Chief Executive Officer. Before co-founding Highline, Mr. Doft worked at Gleacher and Co., Inc. where his time was predominantly spent helping firms consider strategic mergers, acquisitions, and restructurings. Mr. Doft received a B.S. from Wharton School and an M.B.A. from Harvard Business School. He currently serves as a member of the Wharton Undergraduate Executive Board. We believe that Mr. Doft is well qualified to serve as a director due to his executive leadership and investment management experience and his expertise in advising firms on strategic mergers, acquisitions, and restructurings. Lance Hirt has served as one of our directors since our inception. Since 2016, Mr. Hirt has served as a Managing Partner at Stonecourt Capital LP, a New York based private investment firm. Previously, from 2003 to 2016, he was a partner at Lindsay Goldberg LLC, a private equity firm, during which time the firm invested $10 billion of equity capital across 35 portfolio companies. Prior to that, he was a Managing Director in the M&A department at Morgan Stanley, where he also served as the Operating Officer for the global M&A Division. Mr. Hirt began his career as a management consultant at Touche Ross & Co. and subsequently practiced law at Sullivan & Cromwell. Mr. Hirt has served on the board of directors of 19 portfolio companies during his 17-year private equity career. His investment experience spans a broad set of industries and geographies. Mr. Hirt graduated from Yeshiva College with a B.A. in Economics and received an M.B.A. from Harvard Business School and a Juris Doctorate from Harvard Law School. Mr. Hirt currently serves as a Trustee of Yeshiva University. We believe that Mr. Hirt is well qualified to serve as a director due to his extensive investment experience. Andrew Rechtschaffen has served as one of our directors since our inception. Since 2017, Mr. Rechtschaffen serves as Founder and Chief Executive Officer of AREX Capital Management, LP, an equities-focused investment firm. Prior to AREX, Mr. Rechtschaffen was a Partner at Greenlight Capital where he was a member of the investment team from 2002 to 2005 and 2011 to 2017, becoming a Partner in 2005 and again in 2014. Between these periods, he was a Managing Director at Citadel Investment Group managing a multi-billion-dollar portfolio in 106 Table of Contents the Principal Strategies Group and the founder of Obrem Capital Management. He began his career as an Associate in Morgan Stanley’s Investment Banking Division. Mr. Rechtschaffen has served as director of Fiesta Restaurant Group, Inc. (Nasdaq: FRGI) since 2020 and currently serves as a director of the Wharton Alumni Executive Board. Mr. Rechtschaffen was awarded the Alan C. Greenberg Young Leadership Award by UJA-Federation of New York, Wall Street & Financial Services Division. Mr. Rechtschaffen graduated from the Wharton School at the University of Pennsylvania, summa cum laude, with a Bachelor of Science degree and an MBA. We believe that Mr. Rechtschaffen is well qualified to serve as a director due to his executive leadership experience and substantial investment management experience. Brett Barth has agreed to serve on our board of directors. Mr. Barth co-founded BBR Partners in 2000 and is a Co-Chief Executive Officer, co-managing the firm and overseeing BBR’s investment approach and implementation. He has extensive experience vetting investment opportunities across the asset class spectrum and through a range of market environments, working with both traditional and alternative investment managers. Mr. Barth is also a member of BBR’s Executive Committee and Investment Committee. Prior to founding BBR, Mr. Barth was in the Equities Division of Goldman Sachs. Previously, he served in Goldman’s Equity Capital Markets groups in New York and Hong Kong. He began his career in Goldman Sachs’ Corporate Finance Department. Mr. Barth has served a s a director of Cowen Inc. since June 2018. Mr. Barth is a trustee of the University of Pennsylvania as well as a member of the Board of Overseers of the Graduate School of Education. He previously served as both the Chair of the Penn Fund, the University of Pennsylvania’s undergraduate annual giving program, and as the Inaugural Chair of the Undergraduate Financial Aid Leadership Council. Mr. Barth is a member of the board and executive committee of the UJA-Federation of New York, he co-chairs the Annual Campaign and he serves on the endowment’s Investment Committee. Mr. Barth was awarded the Alan C. Greenberg Young Leadership Award by UJA-Federation of New York, Wall Street & Financial Services Division. Mr. Barth graduated summa cum laude with concentrations in Finance and Accounting from the Wharton School of the University of Pennsylvania. We believe Mr. Barth is well qualified to serve on our board of directors due to his extensive investment and wealth management expertise. Lloyd Dean has agreed to serve on our board of directors. Mr. Dean has served as Chief Executive Officer of CommonSpirit Health, one of the nation’s largest non-profit healthcare systems, since February 2019 when CommonSpirit Health merged with Dignity Health, where Mr. Dean served Chief Executive Officer since June 2000. Prior to that, Mr. Dean served as Chief Operating Officer of Advocate Health Care, a healthcare organization, from 1997 to 2000. Mr. Dean has served on the board of directors of McDonald’s Corporation since 2015 and previously served on the boards of Navigant Consulting, Inc., Wells Fargo & Company, the Bar Area Council, the Catholic Health Association of the U.S., Mercy Housing California, and Cytori Therapeutics. Mr. Dean is Co-Chair of the California Future Health Workforce Commission, an organization composed of senior leaders from California’s leading health philanthropies. In 2019, California Governor Gavin Newsom appointed Mr. Dean to his Task Force on Business and Jobs Recovery, and he is the Board Chair for the Committee on Jobs, an organization that brings employment to the San Francisco Bay Area. We believe Mr. Dean is well qualified to serve on our board of directors due to his leadership, management, healthcare and strategic experience, including service on public company boards of directors. Steven Klosk has agreed to serve on our board of directors. Mr. Klosk has served as a director of Cambrex Corporation (formerly NYSE: CBM), a leading global small molecule contract development and manufacturing organization (“Cambrex”), since 2008, and served as its President and Chief Executive Officer from 2008 until its acquisition by Permira in December 2019. Having joined Cambrex in 1992, Mr. Klosk held positions of increasing responsibility, including Executive Vice President, Administration, through 2005, when he assumed direct responsibility for the leadership of the Biopharmaceutical Business Unit as Chief Operating Officer. In August 2006, Mr. Klosk assumed the responsibility of the Pharma business as Executive Vice President and Chief Operating Officer – Biopharma & Pharma, and in February 2007 was appointed to Executive Vice President, Chief Operating Officer and President, Pharmaceutical Products and Services, the last role he held prior to being appointed President and Chief Executive Officer. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School. Mr. Klosk has served on the board of directors of Caladrius Biosciences, Inc. (Nasdaq: CLBS) since 2014. We believe Mr. Klosk is well qualified to serve on our board of directors due to his diversified management experience, particularly in the biopharmaceutical field. 107 Table of Contents Number and Terms of Office of Officers and Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of members. Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. The term of office of the first class of directors, consisting of and , will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of and , will expire at our second annual meeting of stockholders. The term of office of the third class of directors, consisting of , will expire at our third annual meeting of stockholders. Prior to consummation of our initial business combination, holders of our Class B common stock will have the right to elect all of our directors and remove members of our board of directors for any reason. Holders of our public shares will not have the right to vote on the election of directors during such time. These provisions of our amended and restated certificate of incorporation may only be amended if approved by holders of a majority of at least 90% of the outstanding shares of our common stock voting at a stockholder meeting. Approval of our initial business combination will require the affirmative vote of a majority of our board directors, which must include a majority of our independent directors. Subject to any other special rights applicable to the stockholders, prior to our initial business combination, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board of directors that includes any directors representing our sponsor then on our board of directors, or by holders of a majority of the outstanding shares of our Class B common stock. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws will provide that our officers may consist of a Chairman of the Board, a Chief Executive Officer, a Chief Financial Officer, a Secretary and such other officers (including without limitation, a President, Vice Presidents, Assistant Secretaries, and a Treasurer) as our board of directors from time to time may determine. Director Independence Nasdaq rules require that a majority of our board of directors be independent within one year of our initial public offering. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which, in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have three “independent directors” as defined in the Nasdaq rules and applicable SEC rules prior to completion of this offering. Our board of directors has determined that each of Brett Barth, Lloyd Dean, Steven Klosk and is an independent director under applicable SEC and Nasdaq rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our officers or directors have received any compensation for services rendered to us. Our sponsor, officers, directors and their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, officers, directors or our or any of their respective affiliates. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting, management or other compensation from the combined company. All compensation will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time such materials are distributed, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our officers after the completion of our initial business combination will be determined by a compensation committee constituted solely by independent directors. 108 Table of Contents We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. The existence or terms of any such employment or consulting arrangements may influence our management’s motivation in identifying or selecting a target business, and we do not believe that the ability of our management to remain with us after the consummation of our initial business combination should be a determining factor in our decision to proceed with any potential business combination. Committees of the Board of Directors Upon the effective date of the registration statement of which this prospectus forms a part, our board of directors will have two standing committees: an audit committee and a compensation committee. The rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee and the compensation committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. The members of our audit committee will be , and . will serve as chairman of the audit committee. Each member of the audit committee is financially literate and our board of directors has determined that qualifies as an “audit committee financial expert” as defined in applicable SEC rules and has accounting or related financial management expertise. We will adopt an audit committee charter, which will detail the purpose and principal functions of the audit committee, including: • assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm’s qualifications and independence, and (4) the performance of our internal audit function and independent registered public accounting firm; • the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other independent registered public accounting firm engaged by us; • pre-approving all audit and non-audit services to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; • reviewing and discussing with the independent registered public accounting firm all relationships the independent registered public accounting firm have with us in order to evaluate their continued independence; • setting clear policies for audit partner rotation in compliance with applicable laws and regulations; • obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1) the independent registered public accounting firm’s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the independent registered public accounting firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; • meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including reviewing our specific disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; • reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and 109 Table of Contents • reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. Compensation Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of directors. The members of our compensation committee will be , and . will serve as chairman of the compensation committee. We will adopt a compensation committee charter, which will detail the purpose and responsibi

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 49.59%
% of Float Held by Institutions 49.59%
Number of Institutions Holding Shares 43

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Toroso Investments LLC 10,378 $100,000 0.0% 0 0.033%
2021-11-16 Citadel Advisors LLC 332,873 $3,260,000 0.0% 0 1.065%
2021-11-16 CNH Partners LLC 287,157 $2,810,000 0.1% -54.8% 0.919%
2021-11-15 Berkley W R Corp 204,321 $2,000,000 0.1% 0 0.654%
2021-11-15 Marshall Wace LLP 1,403,469 $13,730,000 0.1% +87.1% 4.491%
2021-11-15 Glazer Capital LLC 3,826 $37,000 0.0% +31,783.3% 0.012%
2021-11-15 Hudson Bay Capital Management LP 454,817 $4,450,000 0.1% -42.1% 1.455%
2021-11-15 Context Advisory LLC 31,167 $310,000 0.0% 0 0.100%
2021-11-12 Periscope Capital Inc. 599,400 $5,830,000 0.2% 0 1.918%
2021-11-12 Wolverine Asset Management LLC 25,615 $250,000 0.0% 0 0.082%
2021-11-12 Security Benefit Life Insurance Co. KS 892,789 $8,730,000 0.5% 0 2.857%
2021-11-12 Macquarie Group Ltd. 1,200,000 $11,740,000 0.0% 0 3.840%
2021-11-10 Goldman Sachs Group Inc. 1,531,549 $14,980,000 0.0% +63.4% 4.901%
2021-11-10 Sycale Advisors NY LLC 150,000 $1,490,000 0.7% 0 0.480%
2021-11-09 Picton Mahoney Asset Management 74,997 $730,000 0.0% 0 0.240%
2021-11-09 Robinson Capital Management LLC 10,378 $100,000 0.1% 0 0.033%
2021-11-09 Basso Capital Management L.P. 332,666 $3,250,000 0.4% 0 1.065%
2021-11-04 Corbyn Investment Management Inc. MD 10,300 $100,000 0.0% 0 0.033%
2021-10-28 Mizuho Securities USA LLC 37,741 $360,000 0.0% -62.1% 0.121%
2021-10-22 Tuttle Capital Management LLC 58,747 $420,000 0.2% -16.4% 0.188%
2021-08-25 Marshall Wace LLP 749,991 $7,240,000 0.0% 0 2.400%
2021-08-17 Wells Fargo & Company MN 9,187 $89,000 0.0% 0 0.029%
2021-08-17 Woodline Partners LP 250,000 $2,410,000 0.0% 0 0.800%
2021-08-17 Millennium Management LLC 328,490 $3,170,000 0.0% 0 1.051%
2021-08-16 Whitebox Advisors LLC 100,000 $970,000 0.0% 0 0.320%
2021-08-16 CNH Partners LLC 635,106 $6,130,000 0.2% 0 2.032%
2021-08-16 Canyon Capital Advisors LLC 500,000 $4,830,000 0.2% 0 1.600%
2021-08-16 Alberta Investment Management Corp 175,000 $1,690,000 0.0% 0 0.560%
2021-08-16 Fir Tree Capital Management LP 1,803,965 $17,410,000 0.7% 0 5.773%
2021-08-16 Radcliffe Capital Management L.P. 300,000 $2,900,000 0.1% 0 0.960%
2021-08-16 Goldman Sachs Group Inc. 937,259 $9,050,000 0.0% 0 2.999%
2021-08-13 Ancora Advisors LLC 12,100 $120,000 0.0% 0 0.039%
2021-08-13 Spring Creek Capital LLC 300,000 $2,900,000 0.1% 0 0.960%
2021-08-13 MYDA Advisors LLC 200,000 $1,930,000 0.5% 0 0.640%
2021-08-13 Qube Research & Technologies Ltd 29,524 $290,000 0.0% 0 0.094%
2021-08-13 OMERS ADMINISTRATION Corp 99,999 $970,000 0.0% 0 0.320%
2021-08-12 NorthRock Partners LLC 58,708 $570,000 0.0% 0 0.188%
2021-08-12 MMCAP International Inc. SPC 100,000 $970,000 0.0% 0 0.320%
2021-08-12 Littlejohn & Co. LLC 49,546 $480,000 0.1% 0 0.159%
2021-08-12 Atalaya Capital Management LP 500,000 $4,830,000 1.3% 0 1.600%
2021-08-12 Commonwealth of Pennsylvania Public School Empls Retrmt SYS 50,000 $480,000 0.0% 0 0.160%
2021-08-12 JPMorgan Chase & Co. 207,570 $2,000,000 0.0% 0 0.664%
2021-08-11 CVI Holdings LLC 50,000 $480,000 0.0% 0 0.160%
2021-08-03 Landscape Capital Management L.L.C. 10,149 $98,000 0.0% 0 0.032%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q QUARTERLY REPORT 2021-11-12 https://www.sec.gov/Archives/edgar/data/1841125/000121390021058708/f10q0921_goldenarrow.htm
10-Q QUARTERLY REPORT 2021-08-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021042891/f10q0621_goldenarrow.htm
8-K CURRENT REPORT 2021-06-04 https://www.sec.gov/Archives/edgar/data/1841125/000121390021031034/ea142256-8k_goldenarrow.htm
10-Q QUARTERLY REPORT 2021-06-04 https://www.sec.gov/Archives/edgar/data/1841125/000121390021031012/f10q0321_goldenarrow.htm
NT 10-Q NOTIFICATION OF LATE FILING 2021-05-17 https://www.sec.gov/Archives/edgar/data/1841125/000121390021027064/ea141059-nt10q_goldenarrow.htm
8-K CURRENT REPORT 2021-05-12 https://www.sec.gov/Archives/edgar/data/1841125/000121390021025841/ea140723-8k_goldenarrow.htm
SC 13G 2021-03-29 https://www.sec.gov/Archives/edgar/data/1841125/000089534521000410/ff201088-13g_goldenarrow.htm
8-K FORM 8-K 2021-03-25 https://www.sec.gov/Archives/edgar/data/1841125/000121390021017801/ea138293_8k-goldenarrow.htm
8-K CURRENT REPORT 2021-03-22 https://www.sec.gov/Archives/edgar/data/1841125/000121390021016991/ea138137-8k_goldenarrow.htm
3 OWNERSHIP DOCUMENT 2021-03-19 https://www.sec.gov/Archives/edgar/data/1841125/000121390021016736/xslF345X02/ownership.xml
424B4 2021-03-18 https://www.sec.gov/Archives/edgar/data/1841125/000121390021016378/f424b40321_goldenarrow.htm
3 2021-03-17 https://www.sec.gov/Archives/edgar/data/1841125/000121390021016181/xslF345X02/ownership.xml
3 2021-03-17 https://www.sec.gov/Archives/edgar/data/1841125/000121390021016179/xslF345X02/ownership.xml
EFFECT 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/999999999521000965/xslEFFECTX01/primary_doc.xml
3 OWNERSHIP DOCUMENT 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015886/xslF345X02/ownership.xml
3 OWNERSHIP DOCUMENT 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015885/xslF345X02/ownership.xml
3 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015884/xslF345X02/ownership.xml
3 OWNERSHIP DOCUMENT 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015883/xslF345X02/ownership.xml
3 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015882/xslF345X02/ownership.xml
3 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015881/xslF345X02/ownership.xml
CERT 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000135445721000349/8A_Cert_GAMC.pdf
8-A12B FOR REGISTRATION OF CERTAIN CLASSES 2021-03-16 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015563/ea137688-8a12b_goldenarrow.htm
CORRESP 2021-03-15 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015343/filename1.htm
CORRESP 2021-03-15 https://www.sec.gov/Archives/edgar/data/1841125/000121390021015341/filename1.htm
S-1/A REGISTRATION STATEMENT 2021-03-11 https://www.sec.gov/Archives/edgar/data/1841125/000121390021014902/fs12021a2_goldenarrow.htm
S-1/A AMENDMENT NO. 1 TO FORM S-1 2021-03-05 https://www.sec.gov/Archives/edgar/data/1841125/000121390021013772/ea136921-s1a1_goldenarrow.htm
S-1 REGISTRATION STATEMENT 2021-02-24 https://www.sec.gov/Archives/edgar/data/1841125/000121390021011410/fs12021_goldenarrow.htm
UPLOAD 2021-02-18 https://www.sec.gov/Archives/edgar/data/1841125/000000000021002064/filename1.pdf
DRS 2021-01-22 https://www.sec.gov/Archives/edgar/data/1841125/000121390021003784/filename1.htm